KevinMD February 2, 2025
Recently, while contemplating the AAPA-AMA scope creep debate, I encountered a quote about GLP1-RAs for obesity: “We need to just really think about it as a chronic disease … to make sure that we try to keep that patient in [ongoing] treatment.” Another obesity medicine specialist reinforced this view: “These drugs are indicated by the FDA so that you could be on it for the rest of your life.”
This perspective becomes more troubling when considering recent AHRQ and CDC data showing men spend 40 percent of their lives on prescription medications, while women spend 60 percent. Even more concerning is how we frame disparities in medication access. When researchers noted lower statin use among non-Hispanic Black men compared to...
Today's Sponsors
Today's Sponsor